September 12, 2025

Cemiplimab Reduces Recurrence in High-Risk cSCC

First adjuvant immunotherapy trial shows 23% absolute reduction in recurrence for resected cutaneous squamous cell carcinoma.

Conexiant

September 12, 2025

Is Alopecia Areata a Marker of Elevated Cardiovascular Risk?

While alopecia has several verified comorbidities, the potential correlation with cardiovascular disease warrants further investigation.

Conexiant

September 12, 2025

Maternal Health and Vitiligo: First Scoping Review Protocol

Protocol outlines review of vitiligo pregnancy outcomes, methods, and planned data mapping.

Conexiant

September 08, 2025

HS Severity Scores Declined With GLP-1 Use

Glucagon-like peptide-1 receptor agonists are linked to consistent hidradenitis suppurativa improvements across symptom, quality-of-life, and weight outcomes.

Conexiant

September 05, 2025

One Dose of Benzathine Penicillin Noninferior for Early Syphilis

Most patients reported local injection-site pain, but serious adverse events were rare and unrelated to benzathine penicillin G treatment.

Conexiant

September 03, 2025

Study Maps Delta-Like Protein 3 and SEZ6 Across Tumor Types

Researchers highlight distinct Delta-like protein 3 and seizure-related 6 homolog patterns in neuroendocrine tumors.

Conexiant

September 02, 2025

Misconceptions Regarding Skin Cancer Risk in the United States

Investigators may have uncovered associations between the reported number of sunburns and sociodemographic characteristics as well as the prevalence of protective skin behaviors adopted by U.S. adults...

The ASCO Post

September 02, 2025

Use of Niraparib in Patients With Advanced Melanoma

Researchers are exploring the early outcomes with niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair.

The ASCO Post

September 02, 2025

Dual Immunotherapy May Improve Progression-Free Survival in Advanced Squamous Cell Carcinoma

A novel immunotherapy combination may improve progression-free survival in patients with advanced cutaneous squamous cell carcinoma compared with avelumab alone, according to findings presented at the...

The ASCO Post